•  
  •  
 

Corresponding Author

Ahmed Badawy Amin

Document Type

Original Article

Abstract

Background: A pulmonary-systemic coronavirus illness (COVID-19) caused by the novel SARS-CoV-2 was initially reported in Wuhan, China, in December 2019. COVID-19 quickly gained international attention as a health issue, and in March 2020, it was classified as a pandemic.

Aim and objectives: Assessment of the incidence of neurological complications after COVID-19 vaccination in the Egyptian population.

Subjects and methods: This prospective cohort study was conducted on a group of 300 Individuals who received the COVID-19 vaccine at Al Hussein Hospital and Kobry El Kobba Medical Complex. The recruitment cycle spanned between February 2022 and October 2022.

Result: Regarding different types of vaccine and onset of neurological symptoms, most cases had (1-7 days) onset by 7.5%, 3.2%, 2.8%, 2.3%, and 1.8% for AstraZeneca, sputnik, Sinofarm, Moderna and Pfizer respectively. The most frequent neurological symptom reported was headache, followed by sensory affection. Limb weakness was the least frequent symptom reported. Among the comorbidities assessed in this study, Hypertension (HTN) was the most common, with diabetes mellitus (DM) following closely behind cardiac disease, renal disease, and hepatic disease.

Conclusion: The most frequent age group was 18-30 years, and the study population was predominantly male. The most prevalent comorbidity among patients was hypertension, although smoking rates were relatively low. Sinofarm was the most common vaccine type administered. Neurological symptoms were reported by a small proportion of participants, with headache being the most frequent symptom.

Keywords

Neurological complications; COVID-19 vaccination

Subject Area

Neurology

Download

Share

COinS